news
Cosentyx®displays a 72 percent reduced arthritis flare risk
Cosentyx® resulted in a 72 percent reduced flare risk for enthesitis-related arthritis and juvenile psoriatic arthritis in a Phase III study.
List view / Grid view
Research & Development (R&D)
whitepaper
Application note: Scale Up Assist can help antibody workflow
This study details the use of the new Scale Up Assist feature of the BioFlo 720 Bioreactor Control System to scale CHO batch cultures.
news
Aimovig®displays superiority over topiramate in migraine study
Amgen announces positive results from the first and only randomised, double-blind, head-to-head study comparing Aimovig® to topiramate.
video
On-demand webinar: Water systems – microbial monitoring
This webinar considers the fundamental importance of water system control within pharma processing and the best control and monitoring practices.
news
Rinvoq® shows positive results in rheumatoid arthritis post-hoc analysis
In the analysis, 34 percent of rheumatoid arthritis patients receiving Rinvoq® achieved Clinical Disease Activity Index (CDAI) remission.
news
Wegovy™ demonstrates sustained weight loss in two-year obesity study
Novo Nordisk's Wegovy™ reduced body weight by 15.2 percent versus 2.6 percent with placebo in Phase IIIb study.
whitepaper
Whitepaper: Impact of a pandemic outbreak on vaccine development approach
This whitepaper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods will not solve.
article
Developing drug pipelines
Kris Sterkens, Company Group Chairman of Janssen EMEA and Managing Director of Janssen Pharmaceutica considers how alterations made to COVID-19 vaccine development procedures could benefit future drug development pipelines.
news
Oral antiviral candidate Paxlovid™ reduces COVID-19 risks by 89 percent
Paxlovid™, Pfizer's investigational oral antiviral candidate, displayed an 89 percent reduction in COVID-19 risks in Phase II/III study.
news
Actimab-A CLAG-M combination displays 100 percent remission rate
Actinium's Actimab-A CLAG-M combination showed a 100 percent remission rate in relapsed or refractory acute myeloid leukaemia patients receiving 0.75 μCi/kg in Phase I study.
article
Developing and delivering live biotherapeutic products
The microbial content of the gut has a well established role in health and disease. In this article, European Pharmaceutical Review’s Hannah Balfour explores the development and formulation of live biotherapeutic products (LBPs), an emerging treatment modality that seeks to capitalise on the interaction between the microbiota and host in…
whitepaper
Press release: Telstar: 360 degrees GMP consultancy & engineering solutions at CPhI
Telstar promotes innovative aseptic production solutions in a setting marked by the new GMP Annex 1.
news
Biktarvy® shows high efficacy against HIV in real-world setting
Gilead's Biktarvy demonstrated a consistently high efficacy of over 95 percent in analyses of the ongoing real-world cohort BICSTaR study.
article
The race to get biotech innovation to market: five steps to success
Achieving prompt and profitable market access for new pharma products has never been more challenging. Next-generation drug launches are increasing in number year on year, creating strong competition, and treatments are becoming more tightly targeted, reducing the size of available markets. In addition, biologic drugs are highly complex and expensive…
video
On-demand webinar: High speed for your material analysis
In this webinar, discover how an innovative 2-in-1 method for material analysis accelerates visual and chemical particle analysis in the pharmaceutical industry.
